MARKET

NMTR

NMTR

9 Meters Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.170
0.000
0.00%
After Hours: 1.160 -0.01 -0.85% 19:59 05/07 EDT
OPEN
1.170
PREV CLOSE
1.170
HIGH
1.240
LOW
1.090
VOLUME
8.95M
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
0.4510
MARKET CAP
279.78M
P/E (TTM)
-1.5709
1D
5D
1M
3M
1Y
5Y
RIOT, MARA, OCGN and MVIS among notable premarket gainers
Scienjoy Holding Corporation (SJ) +29% on launching Non-Fungible Tokens on its platforms.MICT (MICT) +17%.Ocugen (OCGN) +15%.BrainsWay (BWAY) +14% on FDA clearance for Deep TMS protocol.China Recycling Energy (CREG) +13%.Axsome Therapeutics (AXSM) +12% on
Seekingalpha · 04/26 12:21
NKLA, SKLZ, OCGN and MVIS among notable premarket gainers
Sypris Solutions (SYPR) +34% on winning contract for deep space program.Silicon Laboratories (SLAB) +16% as Skyworks buys Infrastructure & Automotive business of the Company.LM Funding America (LMFA) +14% on plans to purchase up
Seekingalpha · 04/23 12:22
CRSP, FSR, KSU and XXII among notable premarket gainers
Kansas City Southern (KSU) +16% on $34B bid from Canadian National.Liquid Media Group Ltd. (YVR) +13% on introduction of its NFT Platform.Obalon Therapeutics (OBLN) +11%.22nd Century Group (XXII) +10%.9 Meters Biopharma (NMTR)
Seekingalpha · 04/20 12:19
9 Meters Biopharma Partners With Duke Clinical Research Institute on Short Bowel Syndrome Drug
MT Newswires · 04/19 15:16
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Resear...
ACCESSWIRE · 04/19 12:22
9 Meters Biopharma enters collaboration deal for bowel syndrome treatment development
9 Meters Biopharma (NMTR) will enter into a collaboration with the Duke Clinical Research Institute to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in
Seekingalpha · 04/19 12:02
BRIEF-9 Meters Biopharma Collaborates With The Duke Clinical Research Institute
reuters.com · 04/19 11:45
9 Meters Biopharma, Inc. Announces Collaboration With Duke Clinical Research Institute To Support 9 Meters' Program In Short Bowel Syndrome; Financial Details Not Disclosed
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research
Benzinga · 04/19 11:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NMTR. Analyze the recent business situations of 9 Meters Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NMTR stock price target is 4.600 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 63
Institutional Holdings: 60.75M
% Owned: 25.40%
Shares Outstanding: 239.13M
TypeInstitutionsShares
Increased
14
10.15M
New
24
22.20M
Decreased
5
1.10M
Sold Out
8
424.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
Sandeep Laumas
Chief Financial Officer/Chief Accounting Officer
Edward Sitar
Other
Patrick Griffin
Director
Michael Constantino
Director
John Temperato
Vice President - Operations
Marc Matejka
Independent Director
Lorin Johnson
Independent Director
Roy Proujansky
Independent Director
Michael Rice
Independent Director
Mark Sirgo
No Data
About NMTR
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.